Clinical Trial Update: Normalization of dyrk1A and APP Function as an Approach to Improve Cognitive Performance and Decelerate AD Progression in DS Subjects: Epigallocatechin Gallate as Therapeutic Tool [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating epigallocatechin gallate (EGCG) to normalize dyrk1A and APP function in individuals with Down syndrome, aiming to impro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Down Syndrome

Drugs mentioned

• Epigallocatechin Gallate (EGCG) (epigallocatechin gallate)

Snippet

Sponsor: Parc de Salut Mar | Conditions: Down Syndrome (DS) | Phase 2 | Status: COMPLETED